Cisplatin/adverse effects Humans *Immunotherapy/adverse effects/methods *Muscles/pathology *Neoadjuvant Therapy/adverse effects Neoplasm Staging *Urinary Bladder Neoplasms/drug therapy/pathology/therapy chemoimmunotherapy immunotherapy meta-analysis muscle-invasive bladder cancer (MIBC) neoadjuvant commercial or financial relationships that could be construed as a potential conflict of interest.

*Cystectomy Humans *Neoadjuvant Therapy Neoplasm Staging Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/pathology/*surgery

Antineoplastic Agents/*therapeutic use Carcinoma Transitional Cell/pathology/*therapy Chemotherapy Adjuvant Cystectomy Cystoscopy Humans Lymph Node Excision Muscle Smooth/*pathology *Neoadjuvant Therapy Neoplasm Invasiveness *Organ Sparing Treatments Progression-Free Survival Proportional Hazards Models *Radiotherapy Adjuvant Survival Rate Urinary Bladder Neoplasms/pathology/*therapy Bladder preserving Cancer Muscle invasive Radical cystectomy Trimodal

Antineoplastic Combined Chemotherapy Protocols/therapeutic use Bayes Theorem Carcinoma Transitional Cell/*drug therapy/pathology/surgery Cisplatin/therapeutic use Cystectomy Deoxycytidine/analogs & derivatives/therapeutic use Doxorubicin/therapeutic use Humans Methotrexate/therapeutic use *Neoadjuvant Therapy Neoplasm Invasiveness/pathology Urinary Bladder Neoplasms/*drug therapy/pathology/surgery Vinblastine/therapeutic use Gemcitabine